Table 1.
Antiretroviral treatment programmes with number of patients, characteristics at baseline, follow-up time, status at end of study and Kaplan-Meier estimates of mortality at one year.
| CEPREF (Abidjan, Côte d’Ivoire) | Gugulethu (Cape Town, South Africa) | Khayelitsha (Cape Town, South Africa) | Lighthouse (Lilongwe, Malawi) | All | |
|---|---|---|---|---|---|
| No. of patients | 2117 (19%) | 1611 (14%) | 4397 (39%) | 3028 (27%) | 11153 (100%) |
| Age (years) | 35 (30–42) | 33 (29–39) | 33 (28–39) | 36 (31–43) | 34 (29–41) |
| Sex | |||||
| Female | 1561 (74%) | 1099 (68%) | 3096 (70%) | 1798 (59%) | 7554 (68%) |
| Male | 556 (26%) | 512 (32%) | 1301 (30%) | 1230 (41%) | 3599 (32%) |
| WHO clinical stage | |||||
| No. with data | 2099 (99%) | 1611 (100%) | 4397 (100%) | 2701 (89%) | 10808 (97%) |
| Advanced | 1712 (82%) | 1251 (78%) | 3637 (83%) | 2599 (96%) | 9199 (85%) |
| Less advanced | 387 (18%) | 360 (22%) | 760 (17%) | 102 (4%) | 1609 (15%) |
| CD4 count (cells/μL) | 129 (50–218) | 101 (48–159) | 100 (45–161) | 127 (55–214) | 111 (48–179) |
| Plasma viral load (log copies/mL) | |||||
| No. with data | 5 (0.2%) | 1588 (99%) | 2732 (62%) | 3 (0.1%) | 4328 (39%) |
| Median (IQR) | - | 4.8 (4.4–5.3) | 5.1 (4.5–5.6) | - | 5.0 (4.5 (5.5) |
| Haemoglobin (g/dL) | |||||
| No. with data | 2111 (99%) | 1457 (90%) | 2879 (65%) | 15 (0.5%) | 6462 (58%) |
| Median (IQR) | 9.5 (8.3–10.7) | 11 (10–12) | 11 (10–12) | - | 10.4 (9–12) |
| Weight (kg) | |||||
| No. with data | 2055 (99%) | 0 | 3997 (91%) | 2773 (92%) | 8825 (79%) |
| Median (IQR) | 52 (46–59) | - | 59 (52–67) | 53 (47–60) | 55 (49–63) |
| Total lymphocyte count (cells/μL) | |||||
| No. with data | 2102 (99%) | 0 | 2374 (54%) | 0 | 4476 (40%) |
| Median (IQR) | 1512 (1040–2112) | - | 1310 (860–1870) | - | 1394 (930–1980) |
| Follow-up (years) | 1864 | 1478 | 4084 | 2482 | 9908 |
| No. transferred | Not recorded | 60 (3.7%) | 67 (1.5%) | 412 (13.6%) | 539 (4.8%) |
| No. lost to follow-up* | 244 (11.5%) | 83 (5.2%) | 121 (2.8%) | 374 (12.4%) | 822 (7.4%) |
| No. died | 185 (8.7%) | 124 (7.7%) | 332 (7.6%) | 271 (8.9%) | 912 (8.2%) |
| One-year mortality (%) | |||||
| Kaplan-Meier estimate (95% confidence interval) | 9.9 (8.6–11.3) | 8.2 (6.9–9.7) | 7.8 (7.0–8.6) | 10.5 (9.4–11.8) | 8.9 (8.4–9.5) |
CEPREF, Centre de Prise en Charge de Recherches et de Formation; WHO World Health Organization Medians (interquartile range, [IQR]), number of patients (%) or estimates (95% confidence interval) are shown.
Maximum follow-up per person is one year
Kaplan-Meier estimates of mortality relate to patients remaining in care.
*
See methods for definition of loss to follow-up